Auto Immune Disease, Cancer, Effects of Chemotherapy, Unspecified Complication of Bone Marrow Transplant
Conditions
Keywords
Cancer, Cryopreservation, Ovarian Function, In Vitro
Brief summary
The purpose of this study is to retrieve and cryopreserve ovarian tissue from females undergoing a treatment that may lead to irreversible loss of ovarian function.
Detailed description
The aim of this preliminary study is to retrieve and properly cryopreserve ovarian tissue for autotransplantation in any premenopausal female whose ovarian function is threatened in a physiological, pathological or iatrogenic manner in an effort to observe the return of ovarian endocrine function and development of egg(s) appropriate for use in in vitro fertilization.
Interventions
PROCEDURERetrieval and Cryopreservation
Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
Sponsors
Medical College of Wisconsin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
3 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient must be female. * Patient must have a disease process where the disease or its treatment adversely affects ovarian function. * Patient must be recommended for this study by their oncologist or specialist. * Patient (or legally authorized representative) must sign an informed consent.
Exclusion criteria
* Patients cannot be male. * Patients must not be HIV positive. * Patient cannot have a poor diagnosis such that she is not expected to survive to adulthood. * Patient cannot have any medical condition that would contraindicate surgery. * Patient cannot have any medical condition that would contraindicate general anesthesia. * Patient cannot have any medical condition that would contraindicate pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Return of hormones produced by the ovarian tissue | 3 months after re-implantation |
Secondary
| Measure | Time frame |
|---|---|
| Development of egg(s) appropriate for use in in vitro fertilization | Participants will be followed through their reproductive years (until the patient reaches 45 years of age) |
Countries
United States
Outcome results
None listed